A share price of Humacyte Inc [HUMA] is currently trading at $3.13, up 3.99%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HUMA shares have gain 4.33% over the last week, with a monthly amount drifted -19.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Humacyte Inc [NASDAQ: HUMA] stock has seen the most recent analyst activity on December 20, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $15 from $12. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 11, 2023, and set its price target to $6. On August 14, 2023, upgrade upgraded it’s rating to Neutral and revised its price target to $3.50 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $6 on June 22, 2023. Piper Sandler downgraded its rating to a Underweight and reduced its price target to $4 on May 16, 2022. Cowen started tracking with a Outperform rating for this stock on October 29, 2021, and assigned it a price target of $17. In a note dated September 24, 2021, Oppenheimer initiated an Outperform rating and provided a target price of $16 on this stock.
Humacyte Inc experienced fluctuations in its stock price throughout the past year between $2.75 and $9.97. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Humacyte Inc [NASDAQ: HUMA] shares were valued at $3.13 at the most recent close of the market. An investor can expect a potential return of 155.59% based on the average HUMA price forecast.
Analyzing the HUMA fundamentals
Gross Profit Margin for this corporation currently stands at 0.35% with Operating Profit Margin at -10.43%, Pretax Profit Margin comes in at -14.17%, and Net Profit Margin reading is -14.17%. To continue investigating profitability, this company’s Return on Assets is posted at -1.33, Equity is 11.69 and Total Capital is -1.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.93 points at the first support level, and at 2.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.30, and for the 2nd resistance point, it is at 3.46.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Humacyte Inc [NASDAQ:HUMA] is 1.10. As well, the Quick Ratio is 1.10, while the Cash Ratio is 0.98.
Transactions by insiders
Recent insider trading involved Constantino Michael T., Director, that happened on Dec 04 ’24 when 4600.0 shares were purchased. President, CEO and Director, Niklason Laura E completed a deal on Nov 19 ’24 to buy 1797.0 shares. Meanwhile, Director Dougan Brady W bought 1797.0 shares on Nov 19 ’24.
